Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 14/20 | 0.63 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7592146 | 1.00 | LCK (0.63) | LCKJAK2JAK3ADRA2BSMN1; SMN2 | |
| SCHEMBL7018638 | 0.93 | LCK (0.65) | LCKJAK2JAK3ADRA2BSMN1; SMN2 | |
| SCHEMBL7023777 | 0.91 | LCK (0.59) | LCKJAK2JAK3ADRA2BSMN1; SMN2 | |
| SCHEMBL7586650 | 0.91 | LCK (0.59) | LCKJAK2JAK3ADRA2BSMN1; SMN2 | |
| SCHEMBL7589949 | 0.90 | LCK (0.60) | LCKJAK2JAK3ADRA2BMKNK1 | |
| SCHEMBL7025461 | 0.90 | LCK (0.60) | LCKJAK2JAK3ADRA2BMKNK1 | |
| SCHEMBL7019607 | 0.88 | LCK (0.59) | LCKJAK2JAK3ADRA2BSMN1; SMN2 | |
| SCHEMBL7024412 | 0.88 | LCK (0.61) | LCKJAK2JAK3ADRA2BSMN1; SMN2 | |
| SCHEMBL7555341 | 0.88 | LCK (0.59) | LCKJAK2JAK3ADRA2BSMN1; SMN2 | |
| SCHEMBL7587154 | 0.88 | LCK (0.61) | LCKJAK2JAK3ADRA2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |
| EP-1206265-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |